ABSTRACT
BACKGROUND: Fosfestrol drip infusion therapy is an available endocrinotherapy for prostate cancer. But since there have been few reports of its use in chronic dialysis patients, the pharmacokinetics of fosfestrol in these patients remains unclear. We conducted fosfestrol drip infusion therapy as an induction therapy in chronic hemodialysis patients with prostate cancer. METHODS: Two male patients were included in this study. One was a 68-year-old man who had been in hemodialysis for 15.7 years and had stage B2 prostate cancer. The other was a 74-year-old man who had been in hemodialysis for 4.4 years and had stage C prostate cancer. A total of 250 mg of fosfestrol was dissolved in 250 mL of 5% glucose solution and administered by drip infusion. The drug was given subcutaneously during 14 consecutive days and a luteinizing hormone-releasing hormone agonist was injected on day 15. RESULTS: Serum fosfestrol levels increased rapidly after the drip infusion was started and remained at high levels during infusion, but fell quickly after the treatment ended. Diethylstilbestrol (DES) was also detected in blood after the infusion was started and its levels peaked when infusion ended. But on the next day, neither fosfestrol nor DES were detected in the blood of the patients. Moreover, neither fosfestrol nor DES was detected in the blood of the two patients before administering fosfestrol on day 15. Fosfestrol was quickly eliminated from the blood after hemodialysis was started, while DES remained in the blood during hemodialysis. The adverse reactions were mild hepatic dysfunction and gynecomastia. CONCLUSIONS: Fosfestrol drip infusion therapy appeared to be safe as an endocrinotherapy for prostate cancer in chronic hemodialysis patients.
Subject(s)
Diethylstilbestrol/analogs & derivatives , Diethylstilbestrol/pharmacokinetics , Kidney Failure, Chronic/blood , Prostatic Neoplasms/drug therapy , Renal Dialysis , Aged , Area Under Curve , Diethylstilbestrol/blood , Diethylstilbestrol/therapeutic use , Humans , Infusions, Intravenous , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/therapy , Male , Prostatic Neoplasms/blood , Prostatic Neoplasms/complications , Treatment OutcomeABSTRACT
A 46-year-old man visited our clinic with the chief complaint of indolent swelling of the left scrotal contents. An elastic hard and fist-sized mass with negative transillumination was palpable in left scrotum, but testis and epididymis were not discriminated. Left high orchiectomy was performed. Tumor was 90 X 55 mm in size and the testis and epididymis at the lower pole of the tumor were intact. Histological diagnosis was leiomyoma and we diagnosed leiomyoma of the spermatic cord. To our knowledge, this is the 5th case reported in Japan.
Subject(s)
Genital Neoplasms, Male/pathology , Leiomyoma/pathology , Spermatic Cord , Genital Neoplasms, Male/surgery , Humans , Leiomyoma/surgery , Male , Middle Aged , OrchiectomyABSTRACT
A total of 82 histologically proven squamous cell carcinomas of the tongue, which were treated by interstitial irradiation (radium) at Chiba Cancer Center from 1973-1982, were reviewed. The cumulative five-year survival rate of all cases was 64%: 78% in Stage I and II group, 68% in Stage III and 47% in Stage IV. Local recurrence was noted in eight cases (10%) and later cervical node metastases in 14 cases 25% in T 1-4 N 0). The incidence of mandibular osteoradionecrosis was 18 cases (22%).
